ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy - Wikidata - wikimedia - TriplyDB

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

http://www.wikidata.org/entity/Q34278209

about

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer.Bladder cancer pharmacogenomics: recent insights and future perspectives.

P2860

Q37021261-F74D825C-4F72-4770-ADB2-1E4A793D2372 Q37722160-48F62345-92B0-4501-9E77-014CFEE73D3A Q38146645-CEAF94CC-532E-4465-8425-9AA702BAE35F Q38728212-FA3108C4-7D5E-4FA1-94A4-18CF7F8738C1 Q49805034-58E8B428-1BF0-41DD-AE57-B7DE5AAE68CC Q50106233-5EBE0763-07B6-462A-ACD7-551AAAA94820 Q51540087-4F63E140-94DE-4008-9904-442DCD7128B4

P2860

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

http://www.wikidata.org/entity/Q34278209

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@ast

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@en

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@nl

type

label

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@ast

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@en

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@nl

prefLabel

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@ast

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@en

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@nl

P1433

Q34278209-A4A212C7-C963-4DF2-AC3A-7AFE3B7BE6A3

P1476

Q34278209-280AA599-986D-43D7-AD19-569C40DCCC70

P2093

Q34278209-09062CBB-9259-444F-A181-273BB2648AD3

Q34278209-21AC95C9-9A5E-46A8-A496-236A479AAC2B

Q34278209-2DB3C906-843D-4C07-B2C5-298FD9634811

Q34278209-35D0076A-E71E-4BA0-97EA-24A7DF8CC9B0

Q34278209-50B01F83-2A96-43DB-A3F5-D5DDB86FA0D6

Q34278209-8339EFC3-4D97-4708-944E-287B055560BE

Q34278209-B4A69D76-AD04-429C-8FCF-6DB3B50DA0F0

Q34278209-C6ABD327-ACD5-48E2-8CDB-474B606A4CCA

Q34278209-CA2A2F72-8939-4621-BCB6-30F04A736A31

Q34278209-EB24C491-75BD-43A6-8140-858F283B211D

P2860

Q34278209-2D789857-E122-454F-A6E9-AB74A4C4E0EB

Q34278209-35E71F71-B0B6-4451-8C33-DE0134F336F4

Q34278209-3DF2DD83-42C4-4C71-9C75-F73951308032

Q34278209-4D140B61-53E1-48E7-9089-184EDBBFF36D

Q34278209-5D76D96E-446A-4AC4-8C7B-2C47F1E06AC7

Q34278209-77B7E3F8-6CA5-4935-A7C7-A0EFFFD05B2C

Q34278209-7ABF1757-1FFC-4750-88EF-A3BC053BBB7C

Q34278209-86443E85-1CEF-4E86-A75E-48539D5C28A7

Q34278209-9428137E-D2A7-487D-8E61-224392FC1DEC

Q34278209-94A31BA0-E897-41DA-A0D1-F67FB40B468A

P2888

Q34278209-374806C1-3EFF-4014-884C-D4361F9C9DAC

P304

Q34278209-34DC0C80-BA04-4153-B2CA-2A804B9A7EB4

P31

Q34278209-396CE9BC-7A9E-427E-9DC4-7FA429AF229C

P356

Q34278209-F1E5E654-449C-48EE-BBB1-A0EF805FF90F

P407

Q34278209-CA95788F-964F-4A3F-8C17-2BB029B1F9D6

P478

Q34278209-9E237A82-1AF8-4479-8D4B-53831068C6F8

P50

Q34278209-8951BEF8-A107-4829-AAD0-DD6A141F97AE

P577

Q34278209-AD37BABA-DBAF-4F95-82DB-19EC6027D4C0

P5875

Q34278209-8A8C0FCE-283A-46F4-B8EF-227F4BB9871F

P6179

Q34278209-882D0895-F3D2-40C4-849E-D77A8FFB9D37

P698

Q34278209-DC6E13C8-70E5-4EDA-A78E-C806AD8E95B9

P921

Q34278209-00F3EDF0-1681-4592-BDF4-C6E5DD6C8932

Q34278209-218E498E-8723-472A-B276-2BC17EAC93C3

P932

Q34278209-860F1851-AC65-413B-BF9A-1DA37B04A592

P356

1471-2407-12-187

P1433

P1476

ERCC1 as a biomarker for bladd ...... fit from adjuvant chemotherapy

@en

P2093

Byong Chang Jeong

http://www.w3.org/2001/XMLSchema#string

Ghee Young Kwon

http://www.w3.org/2001/XMLSchema#string

Han Yong Choi

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Hyun Moo Lee

http://www.w3.org/2001/XMLSchema#string

Jisuk Jo

http://www.w3.org/2001/XMLSchema#string

Jong-Mu Sun

http://www.w3.org/2001/XMLSchema#string

Se Hoon Park

http://www.w3.org/2001/XMLSchema#string

Seong Il Seo

http://www.w3.org/2001/XMLSchema#string

Seong Soo Jeon

http://www.w3.org/2001/XMLSchema#string

P2860

Bladder cancer: narrowing the gap between evidence and practice

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

P2888

1471-2407-12-187

P304

187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-187

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225055319

http://www.w3.org/2001/XMLSchema#string

P6179

1045192398

http://www.w3.org/2001/XMLSchema#string

P698

22616552

http://www.w3.org/2001/XMLSchema#string

P921

P932

3404914

http://www.w3.org/2001/XMLSchema#string